The investment seeks to track the performance of a benchmark index. The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index (IMI)/Health Care 25/50, an index made up of stocks of large, mid-size, and small U.S. companies within the health care sector, as classified under the Global Industry Classification Standard (GICS). The Advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index. The fund is non-diversified.
Inception Date: 26/01/2004
Primary Benchmark: MSCI US IMI/Health Care 25-50 GR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.1%
Management Expense Ratio: 0.10 %
|JNJ||Johnson & Johnson||9.12 %|
|UNH||UnitedHealth Group Incorporated (DE)||6.15 %|
|PFE||Pfizer Inc.||5.86 %|
|MRK||Merck & Company Inc. (new)||4.31 %|
|ABBV||AbbVie Inc.||4.14 %|
|AMGN||Amgen Inc.||3.16 %|
|MDT||Medtronic plc.||2.91 %|
|ABT||Abbott Laboratories||2.72 %|
|GILD||Gilead Sciences Inc.||2.53 %|
|BMY||Bristol-Myers Squibb Company||2.29 %|
|XLV||SPDR Select Sector Fund - Heal..||0.14 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IHI||iShares U.S. Medical Devices||0.44 %||
|IYH||iShares U.S. Healthcare||0.44 %||
|FBT||First Trust Amex Biotech Index..||0.56 %||
|IXJ||iShares Global Healthcare||0.48 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|HQH||Tekla Healthcare Investors||0.00 %||
|THQ||Tekla Healthcare Opportunies F..||0.00 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||12.28%||64%||D||59%||F|
|Risk Adjusted Return||112.04%||89%||B+||82%||B-|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
There is nothing we particularly dislike